New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
05:55 EDTTA, TA, OPTT, OPTT, KIRK, KIRK, GLP, GLP, DYN, DYN, DSX, DSX, CORE, CORE, CBRX, CBRX, CBLI, CBLI, ADES, ADESCompanies reporting Before the Market Open on Thursday, March 14
Notable companies reporting before the opening bell on Thursday include ADA-ES (ADES), Cleveland BioLabs (CBLI), Columbia Laboratories (CBRX), Core-Mark Holding (CORE), Diana Shipping (DSX), Dynegy (DYN), Global Partners (GLP), Kirkland's (KIRK), Ocean Power Technologies (OPTT), and TravelCenters of America (TA).
News For ADES;CBLI;CBRX;CORE;DSX;DYN;GLP;KIRK;OPTT;TA From The Last 14 Days
Check below for free stories on ADES;CBLI;CBRX;CORE;DSX;DYN;GLP;KIRK;OPTT;TA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:12 EDTCBLICleveland BioLabs announces successful completion of Phase 1 study of CBL0102
Cleveland BioLabs announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. All patients had tumors involving the liver. CBL0102 is being developed by Incuron, a joint venture between Bioprocess Capital Ventures and Cleveland BioLabs. The primary objective of the study was to evaluate for a maximum tolerated dose and dose-limiting toxicities of CBL0102 in patients with advanced cancers. Secondary objectives were to characterize the drug's safety and to profile its pharmacokinetics. The study also assessed for preliminary evidence of CBL0102 antitumor activity. In particular, the study was designed to explore potential effects related to CBL0102's high relative biodistribution into the liver and therefore included only patients with primary or metastatic liver cancers. Patients were enrolled to receive sequentially higher starting doses of CBL0102 in seven cohorts. Study participants were treated with CBL0102 given orally daily. Patients could continue therapy for eight weeks, or longer if they appeared to be benefiting from therapy.
April 15, 2014
05:59 EDTDSXScorpio, Diana Shipping trade well below NAV, says Deutsche Bank
Deutsche Bank says shares of Scorpio Bulkers (SALT) and Diana Shipping (DSX) are trading well below their net asset values following the recent pullback in the names. Deutsche points out that new and secondhand dry bulk asset prices have increased materially since the end of 2013. It reiterates Buy ratings on both stocks.
April 14, 2014
10:02 EDTOPTTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:16 EDTOPTTOcean Power initiated with a Buy at H.C. Wainwright
Subscribe for More Information
April 9, 2014
12:16 EDTDYNDynegy to host investor day
Subscribe for More Information
April 8, 2014
08:15 EDTADESADA-ES receives notice from NASDAQ due to failure to file Form 10-K by April 1
Subscribe for More Information
April 4, 2014
12:00 EDTOPTTOcean Power falls 21.3%
Ocean Power is down 21.3%, or 81c, to $2.99
10:02 EDTDYNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:00 EDTOPTTOcean Power falls 18.7%
Subscribe for More Information
09:13 EDTOPTTOn The Fly: Pre-market Movers
HIGHER: Mylan (MYL), up 6.8% after report of desire to buy Swedish rival Meda, which confirmed it had been in talks with Mylan but rejected the company's takeover offer. Shares of Mylan were also upgraded to Buy this morning at Citigroup... Mercury Systems (MRCY), up 8.8% after Reuters said Boeing (BA) is considering a takeover bid of the supplier..Micron (MU), up 3% after reporting earnings and revenue that topped expectations... Align (ALGN), up 6% after winning patent case against ClearCorrect... GameStop (GME), up 2.8% following upgrade at BofA Merrill Lynch... Potbelly (PBPB), up 4.6% after upgrade at William Blair.... SYNNEX (SNX), up 18.5% after earnings report. LOWER: CarMax (KMX), down 3.3% after reporting earnings and revenue that fell below expectations... Halozyme (HALO), down 33% after announcing temporary halt of Phase 2 trial enrollment for PEGPH20... Ocean Power (OPTT), down 15% after 3.8M share Spot Secondary priced at $3.10.
09:00 EDTOPTTOcean Power falls 15.5%
Subscribe for More Information
08:31 EDTOPTTOcean Power 3.8M share Spot Secondary priced at $3.10
Roth Capital acted as sole book running manager for the offering.
06:26 EDTDYNDynegy upgraded to Neutral from Sell at UBS
Subscribe for More Information
April 3, 2014
16:30 EDTOPTTOcean Power files automatic common stock shelf
Subscribe for More Information
10:10 EDTOPTTOcean Power mentioned cautiously by The Street Sweeper
Subscribe for More Information
April 2, 2014
08:41 EDTDYNWolfe Research to hold a conference
Power & Gas Deep Dive Conference is being held in Dallas, Texas on April 2.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use